For me, today's efficacy data strengthens the Lero
Post# of 148263
It really took guts for a company like CYDY to entry the fray in the mild to moderate COVID population. Nobody knows ahead of time if the drug will work in a novel virus, and imagine the beating the company would take if it did not work. A management team trying to con investors would not do this. In contrast, this management team really believes in the potential of Leronlimab and are willing to put it out there for one indication after another. My hat's off to them.
In Top Gun verbiage, its almost like their egos are writing checks their bodies can't cash. But Leronlimab has consistently and safely delivered each time.